Anthracycline antibiotics such as daunorubicin, doxorubicin, aclacinomycin, and retracenomycin are clinically and commercially important anticancer agents. 1,2) Yet, their cardiotoxic nature limits their therapeutic utility. 3) This detrimental side effect has led to an intensive search for novel anthracyclines, either by screening of blocked mutants [4] [5] [6] or by a hybrid biosynthetic approach. 7, 8) The biosynthetic approach revealed a new anthracycline antibiotic, designated as 11-hydroxyaclacinomycin X (ID-6105), isolated from the culture broth of Streptomyces galilaeus ATCC 31133. 9-11) ID-6105 was identified as 7-(O-rhodosaminyl-deoxyfucosylrednosyl)-aklavinone ( Fig. 1) .
ministered into the femoral vein at a dose of 2 or 10 mg/kg. Blood (200 ml) was collected into heparinized tubes from the femoral artery 1, 2, 3, 5, 10, 15, 20, 30, 60, 120, 240, 260, 480 and 720 min after the i.v. bolus dose. The blood samples were centrifuged for 15 min at 1500 g and the plasma was harvested. Immediately after the collection of the plasma samples (80 ml), aclacinomycin-A (10 ml, 100 mg/ml) was added to each plasma test tube as an internal standard. Methanol (3 ml) was then added to precipitate the proteins and extract the compounds of interest. These mixtures were vortexed for 15 min and centrifuged for 15 min at 1500 g. The supernatants were withdrawn, dried under a stream of dry nitrogen and reconstituted in 150 ml mobile phase for quantitative HPLC analyses.
Analysis of Biliary, Urinary and Fecal Excretion of ID-6105 in Rats Under light pentobarbital sodium anesthesia, the femoral vein was cannulated with PE-50 polyethylene tubing for ID-6105 administration. A catheter (PE-10, Intramedic, Clay Adams, U.S.A.) was then implanted into the bile duct via a small abdominal incision. Blank bile was obtained just before the administration of 2 or 10 mg/kg ID-6105 to three sets of rats via the femoral vein. Bile was collected 0-1, 1-2, 2-4, 4-6, 6-8, 8-12, 12-24, and 24-48 h after the dose was administered. Urine or feces was collected with the use of metabolic cages over the 72 h after ID-6105 administration and stored at Ϫ70°C until analysis. The ID-6105 levels in the bile, urine and feces were determined as described above.
Determination of the Tissue Distribution of ID-6105 in Rats The rats were decapitated 2, 8, 24, and 48 h after i.v. bolus administration of ID-6105 (2 or 10 mg/kg), respectively. The liver, kidney, adrenal gland, stomach, small intestine, large intestine, spleen, heart, lung, trachea, thymus, brain, testis, muscle, and skin were immediately removed, blotted onto filter papers, and weighed. The tissues were minced in a ice-cold 50 mM Tris-HCl buffer (containing 0.25 M sucrose, pH 7.4) and homogenized with a glass Potter-Elvehjem-type homogenizer with a Teflon pestle. After extracting 100 ml of 20% homogenate with 3 ml methanol, the concentration of ID-6105 in the supernatant was measured as described above.
Administration of ID-6105 and Analysis of ID-6105 Plasma Levels in Beagle Dogs ID-6105 dissolved in 2 ml of physiological saline was administered into the femoral vein at a dose of 0.5 or 2.5 mg/kg. Blood (500 ml) was collected into heparinized tubes from the jugular vein 1, 2, 5, 10, 15, 20, 30, 60, 120, 240, 260, 480 and 720 min after the i.v. bolus dose. The blood samples were centrifuged for 15 min at 1500 g and the plasma was harvested. Immediately after collection of the plasma samples, ID-6105 levels in the plasma were measured as described above.
Pharmacokinetic Analysis ID-6105 plasma concentration profiles after i.v. bolus administration were analyzed by fitting the data to the following biexponential equation according to the nonlinear least-squares method (MULTI) 12) : C p ϭA · exp(Ϫat)ϩB · exp(Ϫbt). The pharmacokinetic parameters were subsequently calculated as follows: k 21 ϭ (AbϩBa)/(AϩB), k el ϭab/k 21 , k 12 ϭ(aϩb)Ϫ(k 21 ϩk el ), t 1/2a ϭ 0.693/a, and t 1/2b ϭ0.693/b, where k 21 represents the transfer rate constant from peripheral to central compartment, k el represents the elimination rate constant, k 12 represents the transfer rate constant from central to peripheral compartment, and t 1/2a and t 1/2b represent the plasma half lives at the a and b phases, respectively. Non-compartmental methods were also used to determine pharmacokinetic parameters. The area under the plasma concentration-time curve from time zero to infinity (AUC) was calculated from the equation AUCϭAUC t ϩC t /b, where C t is the last quantifiable concentration. The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC t ) was calculated by linear trapezoidal approximation. The following parameters were also calculated using the standard methods: the total plasma clearance (CL t )ϭdose/AUC, the steady-state volume of distribution (V dss )ϭCL t · MRT, the mean residence time (MRT)ϭ AUMC/AUC, where AUMC represents the area under the moment curve.
Statistical Analysis Two means were compared by the unpaired Student's t-test. One-way analysis of variance was used to test for significant differences between groups. Statistical significance was defined as pϽ0.05. Figure 2 illustrates typical chromatograms of ID-6105 and the internal standard (IS) in plasma, bile, urine, feces and liver homogenate samples. The blank samples show no peaks that interfere with the ID-6105 and IS signals. To determine the linearity of the HPLC method, quality control samples were prepared, five for each of six ID-6105 concentrations ranging from 0.02 to 100 mg/ml. These samples were assayed on the day of preparation and on the following four consecutive days. Mean regression equations were calculated from the resulting nine calibration curves. For the samples prepared in plasma, bile, urine, feces and liver homogenate, the mean regression equations were yϭ0.912xϪ0.0148 (r 2 ϭ0.999), yϭ0.947xϩ 0.0132 (r 2 ϭ0.999), yϭ0.925xϩ0.0174 (r 2 ϭ0.999), yϭ 0.915xϩ0.0146 (r 2 ϭ0.999), and yϭ0.951xϩ0.00975 (r 2 ϭ 0.999), respectively, where y is the peak area ratio and x is the concentration. These equations show significant linearity (pϽ0.001) over the concentration range of 0.02-100 mg/ml.
RESULTS

Validation of the HPLC Method for Estimation of ID-6105 Levels in Biological Samples
The between-day results of the quality control samples in plasma, bile, urine and liver homogenate indicate the reproducibility of the assay. Variations from the actual concentration, which indicate the precision of the assay, never exceeded 15% (min: 0.708%, max: 8.63%). Moreover, the mean values were always within Ϯ15% deviation of the actual values (min: 2.19%, max: 11.2%), which demonstrate the accuracy of the assay. The same acceptance criteria were fulfilled for the within-day results, which demonstrate the repeatability of the method. The lower limit of quantification (LOQ) was, therefore, defined as 0.02 mg/ml.
The mean absolute recoveries of ID-6105 in plasma, bile, urine, feces and liver homogenate (0.02, 0.1, 0.2, 1, 10, 100 mg/ml) were over 93.7%. ID-6105 in rat plasma, bile, urine, feces and liver homogenate also proved to be stable over three days at 4°C as no significant degradation was observed. Thus, the integrity of samples obtained at various time points and stored at 4°C was demonstrated.
Pharmacokinetic Characteristics of ID-6105 after i.v. Figure 3 shows the concentrations of ID-6105 over time in rat plasma after i.v. bolus administration at a dose of 2 or 10 mg/kg. ID-6105 rapidly disappeared from the plasma by 10 min (a phase) after i.v. administration, followed by late disappearance in the b phase. The pharmacokinetic parameters of ID-6105 after i.v. administration to rats are summarized in Table 1 . The mean plasma half-lives (t 1/2 ) of ID-6105 at the a and b phases when administered at a dose of 2 mg/kg were 0.780 and 17.8 min, respectively. The corresponding values for the dose of 10 mg/kg were 0.911 and 176 min, respectively. The pharmacokinetic parameters were also determined by non-compartmental methods. The CL t values significantly decreased with the increase in dose. In contrast, the V dss values increased about 4 times with the increase in dose from 2 to 10 mg/kg. Biliary, Urinary, and Fecal Excretion of ID-6105 after Figure 4A shows the cumulative amount of ID-6105 excreted in the bile after i.v. bolus administration at a dose of 2 or 10 mg/kg. The cumulative amount of ID-6105 in the bile increased non-linearly as the dose was increased. The cumulative amounts of ID-6105 excreted in the bile 48 h after administering 2 and 10 mg/kg were 0.535 and 1.86 mg/kg, respectively. These values represent 26.7 and 18.5% of the ID-6105 that was administered, respectively.
Administration to Rats
i.v. Administration to Rats
The urinary excretion of ID-6105 was maintained for up to 48 h after i.v. bolus administration to rats at a dose of 2 or 10 mg/kg (Fig. 4B) . The cumulative amount of ID-6105 in the urine 72 h after dosage represented 16.5% of the amount excreted in the bile 48 h after dosage, indicating that i.v. administered ID-6105 was mainly excreted in the bile. The cumulative amounts of ID-6105 excreted in the urine 72 h after administering 2 and 10 mg/kg were 0.0865 and 0.307 mg/kg, respectively. These values represent 4.33 and 3.07% of the ID-6105 that was administered, respectively. On the other hand, ID-6105 was not detected in the feces after i.v. bolus administration to rats at a dose of 2 or 10 mg/kg.
Tissue Distribution of ID-6105 in Rats
The distribution of ID-6105 in various tissues 2, 8, 24, and 48 h after i.v. bolus administration of 2 or 10 mg/kg is summarized in Tables 1 and 2, respectively. ID-6105 was mainly distributed to the kidney, lung, spleen, adrenal gland, and liver after i.v. bolus administration. Moreover, the ID-6105 concentration in the kidney or lung 2 h after i.v. bolus administration was about 13-15 and 20-36 mg/g tissue, which is comparable to the concentration in the plasma shortly after i.v. bolus administration of 2 or 10 mg/kg, respectively (Fig. 3) . The ID-6105 concentrations in various tissues 48 h after i.v. bolus administration were below 1 mg/g tissue (except spleen) and 1.2 mg/g tissue (except spleen and thymus) for the dose of 2 and 10 mg/kg, respectively. The ID-6105 concentration in the testis was below 0.12 and 0.44 mg/g tissue, while ID-6105 was not detected in the brain (in other words, the ID-6105 concentration in the brain was below the quantifiable limit).
Pharmacokinetic Characteristics of ID-6105 after i.v. Administration to Beagle Dogs Figure 5 shows the concentrations of ID-6105 over time in beagle dog plasma after i.v. bolus administration at a dose of 0.5 or 2.5 mg/kg. ID-6105 rapidly disappeared from the plasma after i.v. administration in a pattern similar to that observed in rats (Fig. 3) . The pharmacokinetic parameters of ID-6105 after i.v. administration in beagle dogs are summarized in Table 4 . The mean Tissue Dose (2 mg/kg) plasma half-lives (t 1/2 ) of ID-6105 at the a and b phases when administered at a dose of 0.5 mg/kg were 0.50 and 46.8 min, respectively. The corresponding values for the 2.5 mg/kg dose were 1.50 and 57.8 min, respectively. However, normalization of AUC over the dose range, CL t , and V dss revealed that increasing the dose did not significantly alter these parameters.
DISCUSSION
The anti-tumor properties of ID-6105 are currently being investigated in clinical trials by a number of pharmaceutical companies [9] [10] [11] and thus, characterization of ID-6105 pharmacokinetic parameters will be highly useful. Consequently, we investigated the pharmacokinetic characteristics of ID-6105 after i.v. administration. The plasma concentration of ID-6105 decreased to below the quantifiable limit (0.02 mg/ml) at 4 and 8 h after i.v. administration in rats following doses of 2 and 10 mg/kg, respectively, and was simulated by the two-compartment model to achieve the best fit ( Fig. 3 , Table 1 ). The CL t decreased with nonlinear pharmacokinetics following a dosage increase from 2 to 10 mg/kg in rats, whereas the CL t was not significantly altered in beagle dogs following a dosage increase from 0.5 to 2.5 mg/kg. The clearance of ID-6105 showed the nonlinear kinetics at the high dose of 10 mg/kg in rats. Such a nonlinearity of the clearance of ID-6105 might be attributable to the increase of V dss following a dosage increase from 2 to 10 mg/kg in rats (Table 1 ). In addition, the saturation in the elimination process in the hepatobiliary transport or urinary excretion may be one reason for the nonlinearity of the clearance of ID-6105. Our preliminary studies by isolated rat hepatocytes suggest that ID-6105 is extensively uptaked into hepatocytes in a concentration dependent manner, and is uptaked via ATP-independent/Na ϩ -dependent transporter (unpublished data). The recovery of ID-6105 from bile or urine in beagle dogs was not examined in this study. However, the nonlinearity of the clearance of ID-6105 was not showed at the dose range from 0.5 to 2.5 mg/kg in rats or beagle dogs. The CL t and V dss in beagle dogs at a dose of 2.5 mg/kg were not different from the values in rats at a dose of 2.0 mg/kg (Tables  1, 4 ). 
